letrozole,palbociclib
pfizer,novartis
['ibrance', 'paloma-2', 'breast', 'pfizer', 'fierce']
#asco22 alas, pfizer's ibrance, didn't meet os endpoint in frontline hr+/her2- breast cancer in the paloma-2 trial. 
Tweets from the Fierce Life Sciences editorial team